Physician profile
Jill K Grounds
NPI 1124254784
$5,592.81
in general payments reported to CMS, 2019-2025
40 companies · $907 in 2025
The $907 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $416 · 2021: $570 · 2022: $691 · 2023: $1,915 · 2024: $685 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,849 · Travel and Lodging: $657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,849.31 |
| Travel and Lodging | $657.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,577.78 | 2021-2025 | Venaseal, Avalus |
| Boston Scientific Corporation | $553.39 | 2019-2025 | Watchman Flx, Bodyguardian |
| Medtronic Vascular, INC. | $397.32 | 2019-2020 | |
| Abbott Laboratories | $332.71 | 2019-2025 | Cardiomems |
| Imperative Care, INC | $236.14 | 2025 | Symphony Catheter |
| Amgen INC. | $208.92 | 2021-2024 | Repatha |
| Actelion Pharmaceuticals US, INC. | $177.99 | 2023 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $173.08 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $163.62 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $151.87 | 2021-2025 | Andexxa, Wainua |
| Terumo Medical Corporation | $150.99 | 2025 | |
| Impulse Dynamics (USA) INC. | $149.99 | 2023 | Optimizer |
| Novartis Pharmaceuticals Corporation | $145.17 | 2019-2025 | |
| Pfizer INC. | $139.12 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.03 | 2021-2025 | Jardiance |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $93.79 | 2020-2024 | Xarelto |
| Abiomed | $93.65 | 2021 | |
| Edwards Lifesciences Corporation | $93.16 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $86.35 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $78.23 | 2019-2021 | |
| Biotronik INC. | $45.45 | 2025 | Amvia Edge, Acticor 7 Vr-T Dx, Biomonitor |
| Kestra Medical Technology Services, INC. | $38.31 | 2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.49 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $32.40 | 2021-2022 | |
| Tactile Systems Technology INC | $30.07 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Baxter Healthcare | $29.86 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $28.75 | 2025 | |
| Medtronic USA, INC. | $25.57 | 2019 | |
| Shockwave Medical, INC | $24.39 | 2022 | |
| Irhythm Technologies, INC. | $24.27 | 2024 | Zio Monitor, Zio Xt Patch |
| Angiodynamics, INC. | $23.05 | 2025 | Alphavac |
| Novo Nordisk INC | $19.23 | 2024 | Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals, Ltd. | $17.82 | 2023 | Arcalyst |
| Cvrx, INC. | $17.29 | 2023 | Barostim Neo System |
| Chiesi USA, INC. | $16.00 | 2025 | Kengreal |
| Scpharmaceuticals INC. | $15.93 | 2025 | |
| Heartflow, INC. | $15.07 | 2024 | |
| Daiichi Sankyo INC. | $14.78 | 2023 | Injectafer |
| Philips North America LLC | $14.49 | 2024 | (Ck7) Extended Holter |
| Cashflow Solutions, LLC | $13.29 | 2023 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Grounds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.